AccuraMed was founded in 2016，which is a high-tech company focusing on the detection and analysis of tissue biological markers, the discovery of innovative tumor drug targets, and the development of clinical and pathological immunodiagnostic testing solutions. Research on tumor immunity related to the current hot spots is committed to providing customers with advanced tumor tissue immune microenvironment analysis solutions. In the future, AccuraMed will continue to carry out in-depth integration and development of products with innovation as the driving force to promote the breakthrough development of tumor immunity, innovative immunotherapy and pathological diagnosis technology, which will bring revolutionary changes to the diagnosis and treatment of tumors.